Treatment of Carcinosarcoma of the Fallopian Tube Mimicking Ovarian Cancer: A Case Report and Genetic Analysis

J Nippon Med Sch. 2021;88(6):574-578. doi: 10.1272/jnms.JNMS.2021_88-608.

Abstract

Carcinosarcoma of the fallopian tube is an exceptionally rare gynecological neoplasm. It tends to have high metastatic potential, to frequently recur, and has a poor prognosis. For these reasons, treatment is difficult and there is no standardized therapy schedule for this disease. Here, we report a case of carcinosarcoma of the fallopian tube mimicking ovarian cancer, initially presenting as a rupture of a growth and subsequent hemoperitoneum. The 55-year-old woman underwent cytoreductive surgery and postoperative conventional platinum-based combination therapy. The anti-angiogenic drug bevacizumab was added, and no evidence of disease was found on follow-up images or tumor markers 51 months after surgical resection. We describe a rare case of carcinosarcoma of the fallopian tube, include an in-depth histopathological review with genetic analysis, and propose treatment with a platinum-based combination therapy including bevacizumab.

Keywords: bevacizumab; carcinosarcoma; fallopian tube; ovarian cancer; platinum.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab / therapeutic use*
  • Carcinosarcoma / diagnosis
  • Carcinosarcoma / drug therapy*
  • Carcinosarcoma / genetics
  • Combined Modality Therapy
  • Cytoreduction Surgical Procedures
  • Fallopian Tube Neoplasms / drug therapy*
  • Fallopian Tube Neoplasms / genetics
  • Fallopian Tube Neoplasms / surgery
  • Fallopian Tubes / diagnostic imaging
  • Fallopian Tubes / surgery*
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / surgery
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Bevacizumab